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WHAT THIS PAPER ADDS?
 Performing endovascular aneurysm repairs in patients outside of stent-graft manufacturer’s instructions for use has been asso-
ciated with poorer outcomes. This is the largest study to date investigating the effects of neck angulation, neck diameter, neck
length, neck ﬂare, and neck thrombus on outcomes following EVAR, and contains the longest follow-up for this subgroup of
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Objectives: This study aims to evaluate outcomes following EVAR in patients with hostile neck anatomy
(HNA).
Methods: Data prospectively collected from 552 elective EVARs were analysed retrospectively. Data
regarding neck morphology was obtained from aneurysm stent plans produced prior to EVAR. HNA was
deﬁned as any of; neck diameter >28 mm, neck angulation >60, neck length <15 mm, neck thrombus,
or neck ﬂare.
Results: 552 patients underwent EVAR. Mean age 73.9 years, mean follow-up 4.1 years. 199 patients had
HNA, 353 had favourable neck anatomy (FNA).
There was a signiﬁcant increase in late type I endoleaks (FNA 4.5%, HNA 9.5%; P ¼ 0.02) and total
reinterventions (FNA 11.0%, HNA 22.8%; P < 0.01), and a signiﬁcant decrease in late type II endoleaks in
patients with HNA (FNA 16.7%, HNA 10.6%; P < 0.05).
There was no signiﬁcant difference in technical success (FNA 0.6%, HNA 2.0%; p ¼ 0.12), 30-day re-
intervention (FNA 2.8%, HNA 5.0%; P ¼ 0.12), 30-day mortality (FNA 1.1%, HNA 0.5%; P ¼ 0.45), 30-day
type I endoleaks (FNA 0.8%, HNA 2.5%; P ¼ 0.12), 5-year mortality (FNA 15.1%, HNA 14.6%; P ¼ 0.86),
aneurysm-related mortality (FNA 1.7% versus HNA 2.0%; P ¼ 0.79), stent-graft migration (FNA 2.5%, HNA
3.0%; P ¼ 0.75), sac expansion (FNA 13.0%, HNA 9.5%; P ¼ 0.22), or graft rupture (FNA 1.1%, HNA 3.5%;
P ¼ 0.05).
Binary logistic regression of individual features of HNA revealed secondary intervention (P ¼ 0.009),
technical failure (P ¼ 0.02), and late type I endoleaks (P ¼ 0.002), were signiﬁcantly increased with
increased neck diameter.
Conclusions: HNA AAAs can be successfully treated with EVAR. However, surveillance is necessary to
detect and treat late type I endoleaks in HNA patients.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.tions on this paper, please go
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Endovascular aneurysm repair (EVAR) has shown a signiﬁcant
beneﬁt in terms of perioperative mortality compared with open
abdominal aortic aneurysm (AAA) repair. Due to these improved
mortality rates, EVAR has permitted AAA surgery in patients withed by Elsevier Ltd. All rights reserved.
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reduced operative time, decreased pain and trauma, reduced length
of stay in the hospital and intensive care unit, and reduced blood
transfusions.3 The disadvantage of EVAR lies with its long-term
complications and re-interventions, due to endoleaks, migration,
anddevice failure,4 necessitating lifelong followup. The feasibilityof
EVAR depends on aortic morphology,5 with most manufacturers’
instructions for use (IFU) stating that EVAR should be performed in
patients with an aortic neck greater than 15 mm length, less than
28 mm diameter, and with an angulation less than 60. Non-
adherence to these guidelines, termed hostile neck anatomy
(HNA), has been associatedwith poorer outcomes, particularly with
regards to type 1 endoleaks,6,7 with neck angulation leading to
a signiﬁcant increase in proximal endoleaks, graft migration, and
secondary interventions.8
A large multicentre study recently demonstrated that liberal-
isation of EVAR to wide or angulated necks was associated with
sac expansion and raised signiﬁcant concerns regarding long term
risk of graft rupture,9 which relates to repressurisation of the
aneurysm sac due to device failure or disease progression in the
regions used to ﬁxate and seal the device.10 The UK EVAR 1 trial11
reported that the previously documented early beneﬁt of EVAR
was lost with longer term follow up, and this was largely due to
late ruptures in the endovascular group. Case selection may
therefore be important, raising questions as to whether EVAR
should only be performed within manufacturers’ IFU. However,
this policy would deny endovascular repair as an option to
a signiﬁcant proportion of AAA patients. Published data on
outcomes of EVAR on hostile necks compared to favourable necks
from a large series are currently lacking. There is also insufﬁcient
long-term data for this subgroup of patients. This study aimed to
evaluate outcomes following hostile neck EVARs, speciﬁcally
those with a neck diameter greater than 28 mm, greater than 60
angulation, less than 15 mm neck length, neck ﬂare, or neck
thrombus, from a large series of consecutive patients over an 11
year period.
Methods
Data prospectively collected from 552 patients who underwent
elective EVAR in a single institution from January 1999 to July 2010
were analysed retrospectively. This included all data from each
consultant, with no exclusions. This cohort included a subset of the
148 patients who were randomised into the UK EVAR 111 or EVAR 2
trials.12 Pre-operatively all patients underwent computed tomog-
raphy (CT) imaging. Aneurysm stent planning maps were produced
prior to EVAR using Voxar 3D (Toshiba Medical Systems, The
Netherlands) and included data on aneurysm neck morphology.
Hostile neck anatomy was deﬁned as a neck diameter greater than
28 mm, greater than 60 angulation, less than 15 mm neck length,
neck ﬂare, or neck thrombus. The proximal aortic neck diameter
was measured just below the renal arteries, from adventitia to
adventitia. The aortic neck angle was measured between the aortic
neck and the longitudinal axis of the aneurysm. Aortic neck length
was measured from just below the renal arteries to the most
proximal dilation of the aneurysm. Neck ﬂare was calculated from
diameter measurements at the proximal and distal ends of the
aortic neck. Completion angiograms were performed for all
patients, with type I endoleaks treated at the time of index
procedure.
A standardised proforma was used to collect data prospec-
tively which was a modiﬁcation of the National Vascular Data-
base AAA proforma (Vascular Society of Great Britain and
Ireland). Data on demographics, lifestyle, comorbidity, procedural
details, perioperative outcomes and other variables were allprospectively entered into a database with the exception of
preoperative creatinine levels which were retrospectively
retrieved from the electronic patient database. Data complete-
ness was excellent with preoperative creatinine levels missing in
only 4 patients.
Baseline characteristics included age and sex; and lifestyle
variables included smoking (past and present). Comorbidities
studied included ischaemic heart disease (history of angina, any
previous myocardial infarct, prior percutaneous coronary inter-
vention, and coronary artery bypass surgery), chronic renal
failure (creatinine levels more than 120 mmol/L), hypertension,
cerebrovascular disease (previous transient ischaemic attack or
stroke), hyperlipidaemia, chronic obstructive pulmonary disease,
and diabetes mellitus (diet or tablet controlled or insulin
dependent types). AAA speciﬁc variables included AAA diameter,
type of repair (EVAR or open), symptoms and morphology (for
EVARs). Medication history included statin or antiplatelet
therapy.
EVAR trial participants were followed up according to the trial
protocol, and were followed up at 1 month, 3 months and annually
after EVAR deployment. At each follow-up appointment, adverse
events were recorded and CT scans were performed.
For non-EVAR trial participants, patients underwent pre-
discharge abdominal radiographs and duplex ultrasound scans,
followed by ultrasound scan surveillance at 3, 6, and 12 months.
Following this all patients were followed up annually with an
abdominal radiograph and USS for life. CT scans were performed as
necessary to conﬁrm or clarify complications detected by ultra-
sound scan surveillance. Prospectively collected data on the results
of ultrasound or CT imaging, and late outcomes on the EVAR
patients, including endoleaks, sac expansion, migration, throm-
bosis and rupture, were entered into a separate EVAR database. This
“endovascular stent clinic” database was then merged with data
previously submitted to the National Vascular Database.
The electronic medical record Isoft Patient Centre Version
4.1.1107 provided patient discharge summaries, clinic letters, and
patient death records. Patient deaths were further cross checked
with mortality data from the Register Ofﬁce of Leicester City
Council. Further supplemental data were obtained from type-
written operation notes, which were prospectively ﬁled according
to year of surgery and patient surnames.
The outcome measures were in accordance with the reporting
standards for EVAR13, 31 and included technical failure, endoleaks,
migration, sac expansion, rupture, 30-day mortality, reinterven-
tions, late all-cause mortality, and late aneurysm related
mortality.Statistical analysis
The datawere analysed using IBM SPSS version 18. Comparisons
between groups were performed using contingency table analysis
with a Chi-square or Fisher exact text (categoric variables) and t
tests (continuous variables) to determine statistically signiﬁcant
differences. The KaplaneMeier method was used to estimate
survival distributions (freedom from reintervention, aneurysm
related mortality and all-cause mortality) for the groups. Cox
regression was used to compare reintervention, total mortality and
aneurysm related mortality. Cox regression analysis was adjusted
for age, gender, smoking history, ischaemic heart disease, hyper-
lipidaemia, statin therapy, COPD, hypertension, diabetes, chronic
renal failure, cerebrovascular disease, ASA grade, AAA diameter,
and AAA length. Binary logistic regression was used to determine
the effect of speciﬁc neck characteristics. An a level of <0.05 was
used to determine statistical signiﬁcance.
Table 2
Baseline characteristics of patients undergoing EVAR.
Favourable neck
N ¼ 353 (SD)
Hostile neck
N ¼ 199 (SD)
P value
Age 73.9 (6.6) 73.9 (7.1) 0.97
Male 326 190 0.19
Ischaemic heart disease 136 91 0.10
Smoker 280 155 0.65
Hypertension 204 124 0.30
Hyperlipidaemia 158 101 0.18
Diabetes 45 23 0.68
Cerebrovascular disease 38 21 0.94
COPD 20 7 0.22
Creatinine >120 mm/L 80 54 0.24
Statin therapy 123 81 0.17
ASA grade 2.12 (1.2) 2.31 (1.3) 0.08
Pre-op AAA diameter
(mm)
64.8 (12.0) 64.2 (9.7) 0.63
AAA length (mm) 99.9 (22.8) 103.5 (21.9) 0.12
Common Iliac 26 18 0.29
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Patient demographics and stent grafts devices
There were 552 (516 males, 93.5%) patients who underwent
EVAR during the study period. The mean follow-up was 4.1 years
(mean FNA 4.1 years, mean HNA 4.2 years). There were 199 patients
(36.1%) who had hostile neck anatomy (Table 1). Comparison of
hostile neck anatomy (HNA) and favourable neck anatomy (FNA)
groups’ baseline characteristics revealed no difference in aneurysm
diameter, aneurysm length, neck length, common iliac artery
diameter greater than 25 mm, common iliac artery length, or any
comorbidities (Table 2).
Stent-graft devices used were Cook Zenith (n ¼ 343), Medtronic
Talent (n ¼ 94), Gore Excluder (n ¼ 66), Medtronic Endurant
(n ¼ 37), Edwards Lifepath (n ¼ 4), Endologix Powerlink (n ¼ 1),
Lombard Aorﬁx (n ¼ 2) and Jotec (n ¼ 1) (Table 3).Artery >25 mm
Right common iliac
artery length (mm)
58.3 (17.3) 58.2 (17.2) 0.98
Left common iliac artery
length (mm)
60.0 (17.4) 60.0 (17.6) 0.98
Follow up (months) 48.8 (28.8) 50.1 (35.6) 0.66
Data are the mean and standard deviation.Outcomes
The clinical outcomes between the favourable and hostile neck
anatomy groups are summarised in Table 4. Early results, occurring
within 30 days, showed no signiﬁcant difference in immediate
technical failure, deﬁned as failure to completely exclude the
aneurysm sac as deﬁned on completion angiogram, in patients with
HNA (FNA 0.6% versus HNA 2.0%; p¼ 0.12), and no difference in 30-
day mortality (FNA 1.1% versus HNA 0.5%; P ¼ 0.45), 30-day type I
endoleaks (FNA 0.8% versus HNA 2.5%; P ¼ 0.12), or 30-day rein-
terventions (FNA 2.8% versus HNA 5.0%; P¼ 0.12). Technical failures
in the FNA group included a type Ia endoleak which was unable to
be excluded with additional stenting, and a failure of limb
deployment which was corrected later. Technical failures in the
HNA group were due to deployment of 2 limbs that were too short,
and 2 maldeployments. However, all cases of technical failure were
prior to 2004.
Outcomes occurring after 30 days postoperatively, revealed an
increase in type I endoleaks (FNA 4.5% versus HNA 9.5%; P¼ 0.02) in
patients with HNA, and a signiﬁcant decrease in the rate of type II
endoleaks (FNA 16.7% versus HNA 10.6%; P < 0.05). There was,
however, no signiﬁcant difference in the rates of type III endoleaks.
Therewas also no increase in the rates of devicemigration (FNA2.5%
versus HNA 3.0%; P ¼ 0.75), sac expansion (FNA 13.0% versus HNA
9.5%; P ¼ 0.22), aneurysm rupture (FNA 1.1% versus HNA 3.5%;
P¼0.05), or5-yearmortality (FNA15.1%versusHNA14.6%;P¼0.86).
There was no signiﬁcant difference in reinterventions (HR 1.91
[0.93e3.90]; P ¼ 0.08), late aneurysm related mortality (HR 2.43
[0.19e31.22]; P ¼ 0.50), or late all-cause mortality (HR 1.03 [0.56e
1.89]; P ¼ 0.92) (Figs. 1e3).Table 1
Breakdown of anatomical characteristics of patients with hostile neck anatomy.
Neck characteristics Number of patients with characteristic
Diameter only 102
Angulation only 17
Length only 9
Flared only 32
Thrombus only 4
Multiple characteristics: 35
Diameter, thrombus and ﬂared 2
Diameter, angulation and ﬂared 3
Diameter and thrombus 2
Flared and angulation 3
Diameter and angulation 1
Diameter and ﬂared 17
Flared and length 1
Diameter and length 6In terms of total number of reinterventions (Table 5) there were
a total of 75 procedures undertaken on 61 patients. Overall there
was a signiﬁcant difference in the number of reinterventions
required for those patients with HNAwhen compared to thosewith
FNA (FNA 11.0% versus HNA 22.8%; P < 0.01). When comparing the
indication for reintervention there was a signiﬁcant difference in
the number of procedures to treat type 1a endoleaks (FNA 0.6%
versus HNA 2.5%; P < 0.05) and also in the number of procedures
required to treat type 2 endoleaks (FNA 1.1% versus HNA 2.0%;
P ¼ 0.04). This was in contrast to type 1b endoleaks, type 3 endo-
leaks, limb occlusion, device migration and graft rupture, where no
signiﬁcance was seen in the difference between FNA and HNA.
Subgroup analysis revealed that there was no association between
type Ib endoleaks and common iliac artery diameter greater than
25 mm (CIA>25 mm 9.1% CIA<25 mm 3.7%; P ¼ 0.10), and no
associationwith right common iliac artery length (P¼ 0.946) or left
common iliac artery length (P ¼ 0.291).
Binary logistic regression of individual features of HNA revealed
secondary intervention (P¼ 0.009), technical failure (P¼ 0.02), and
late type I endoleaks (P ¼ 0.002), were signiﬁcantly increased in
patients with increased neck diameter. Further analysis comparing
patients with large neck diameter (LD), other hostile neck charac-
teristics and those with FNA validated the ﬁndings of the binary
logistic regression, with secondary intervention (LD 17.3% Other
HNA 9.1% FNA 14.6%; P ¼ 0.040), technical failure (LD 3.0% Other
HNA 0% FNA 2.0%; P ¼ 0.046), and late type I endoleaks (LD 12.0%
Other HNA 4.5% FNA 9.5%; P ¼ 0.008) remaining signiﬁcantly
increased in patients with large neck diameter.Table 3
Stent-grafts utilised in the favourable and hostile neck groups.
Stent graft device Favourable neck
N ¼ 353
Hostile neck
N ¼ 199
Zenith (Cook Medical Europe) 228 (64.6%) 115 (57.8%)
Talent (Medtronic, Minneapolis) 48 (13.6%) 46 (23.1%)
Excluder (Gore) 53 (15.0%) 13 (6.5%)
Endurant (Medtronic) 17 (4.8%) 20 (10.1%)
Lifepath Edwards 4 (1.1%) 0 (0%)
Powerlink Endologix 1 (0.3%) 0 (0%)
Aorﬁx Lombard 2 (0.6%) 0 (0%)
Jotec Tube 0 (0%) 1 (0.5%)
% equates to proportion of stents of that make in each group.
Figure 2. KaplaneMeier estimates for all cause mortality.
Table 4
Analysis of clinical outcomes for hostile and favourable necks.
Favourable
neck (%) N ¼ 353
Hostile neck (%) N ¼ 199 P value
Technical failure 2 (0.6) 4 (2.0) 0.12
30 day re-intervention 10 (2.8) 10 (5.0) 0.19
30 day mortality 4 (1.1) 1 (0.5) 0.45
30 day type I endoleak 3 (0.8) 5 (2.5) 0.12
5 year mortality 54 (15.1) 29 (14.6) 0.86
Aneurysm relatedmortality 6 (1.7) 4 (2.0) 0.79
Type I endoleak 16 (4.5) 19 (9.5) 0.02
Type II endoleak 59 (16.7) 21 (10.6) <0.05
Type III endoleak 1 (0.3) 3 (1.5) 0.10
Migration 9 (2.5) 6 (3.0) 0.75
Sac expansion 46 (13.0) 19 (9.5) 0.22
Rupture 4 (1.1) 7 (3.5) 0.05
Reintervention 33 (9.3) 29 (14.6) 0.06
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This study into EVAR outcomes for patients with HNA contains
the longest follow-up for this subgroup of patients. This has
revealed that there was an increased risk of type I endoleaks when
EVAR was performed in patients with hostile necks; however there
was no increase in 30-day mortality, late aneurysm related
mortality or late all-cause mortality. Although one may expect an
increase in type 1 endoleaks in this cohort of patients, this obser-
vation is not consistently found, and the subgroup analysis of type I
endoleaks revealed that the increase was primarily in type Ia
endoleaks, rather than type Ib, as would be expected in patients
with HNA. Binary logistic regression also identiﬁed that increased
neck diameter was more likely to lead to a type I endoleak.
Previous studies have looked at mortality rates following EVAR
in angulated and wide aortic necks, with 8 papers identifying no
increase in less than 30 day mortality,6,8,14e19 or late mortality, in
accordance with our study. The incidence of type I endoleaks
following EVAR is of critical importance due to the risk of sac
expansion and rupture20 if left untreated, and the need for
secondary interventions to prevent this. Our results showed an
increased risk of late type I endoleaks, principally due to type Ia
endoleaks, although type Ib endoleaks were more common overall.
This increase in type I endoleaks was also identiﬁed in largerFigure 1. KaplaneMeier estimates for freedom from reintervention.studies by Hobo8 and Aburahma,17 but not found in smaller studies
by Choke,16 and Fairman.21 Although type Ib endoleaks were not
found to be increased in patients with HNA, they were the most
common form of type I endoleak identiﬁed in this study. Schanzer9
identiﬁed CIA diameter greater than 20 mm as associated with sac
expansion, however type Ib endoleaks were not associated with
a signiﬁcant increase in CIA diameter in this study. A study by
Hoshina22 has shown that early type I endoleak rates can be
signiﬁcantly decreased by the judicious use of intraoperative
adjuncts in both FNA and HNA. Hoshina’s study showed that
intraoperative adjuncts decreased the rate of type I endoleaks at 1
year follow up to 0%. Consequently it is likely that as the use of
intra-operative adjuncts to prevent early type I endoleaks
improves, the surgical techniques will be developed to decrease the
rate of early type I endoleaks in patients with HNA.
It is logical to think that patients with HNAwould be more likely
to require intraoperative adjuncts and reintervention due to theFigure 3. KaplaneMeier estimates for aneurysm related mortality.
Table 5
Reintervention procedures performed and reasons for reintervention.
Reintervention procedures N FNA n ¼ 353 HNA n ¼ 199 P value
Distal type I endoleak (Extension n ¼ 21; Redo EVAR n ¼ 1; Occluder and crossover graft n ¼ 1) 23 11 (3.1%) 12 (6.0%) 0.10
Proximal type I endoleak (Cuff extension n ¼ 5; Palmaz Stent n ¼ 1; Coil embolization n ¼ 1) 7 2 (0.6%) 5 (2.5%) <0.05
Type II endoleak (Sac embolization n ¼ 2; Embolization/Clipping IMA n ¼ 2;
Embolization of lumbar artery n ¼ 1)
5 1 (1.1%) 4 (2.0%) 0.04
Type III endoleak 2 1 (0.6%) 1 (0.5%) 0.68
Limb occlusion (Crossover graft n ¼ 12; Embolectomy n ¼ 1; Axillobifem for stent
occlusion n ¼ 1; Limb stenosis/kink wall stent and angioplasty n ¼ 5)
19 12 (3.4%) 7 (3.5%) 0.94
Migration (Extension n ¼ 11; Redo n ¼ 3; Balloon moulding n ¼ 1) 15 9 (2.5%) 6 (3.0%) 0.20
Ruptured graft (Redo EVAR n ¼ 3; Open repair n ¼ 1) 4 2 (0.6%) 2 (1.0%) 0.56
Total 75 38 (11.0%) 37 (22.8%) <0.01
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reported.However, the reintervention rates inpatientswithHNAare
of some debate. Two studies have both concluded that reinterven-
tion rates are higher in patients with HNA,8,23 however four studies
have contradicted this.14e16,18 Due to the variability of these results,
with each paper using slightly different characteristics to deﬁne
HNA, further research into this area is required before deﬁnitive
conclusions can be drawn. Although our study revealed no signiﬁ-
cant difference in the number of patients requiring reintervention,
there was an increase in the total number of interventions per-
formed in patients with HNA. It should however be noted that the
majorityof these reinterventionswere for type II endoleaks and type
Ib endoleaks, which are unlikely to be directly related to HNA. There
was also no difference in the rate of reinterventions for stent-graft
migration, or graft rupture, however the increased reintervention
rate in patients with type Ia endoleaks who had HNA in our series
reﬂects the practice in our unit of aggressively and urgently treating
the increased type I endoleaks in this group of patients. This is the
likely reasonwhyhostile neckpatients didnotexhibit anydifference
in aneurysm related mortality to the favourable neck group despite
having an increased rate of type I endoleaks, and underscores the
need foreffective surveillance so that suchpatients canbeaccurately
diagnosedwith seriousgraft complicationsandeffectively treated to
prevent rupture and graft-related death. A further area for research
highlighted by the results of this study is whether there is a role for
increasing the intensity of postoperative surveillance in patients
with HNA.
A major concern post EVAR is sac expansion. Studies by Cho,24
Haider,25 and Tanski26 have revealed that sac expansion occurs in
0e1.1% of patients undergoing EVAR at 1 year, and 43% at 4 years,
with other reports identifying that change in sac size following
EVAR is dependent on the type of endograft used.27e29 Four studies
have looked at sac expansion ﬁnding no increased risk of sac
expansion with HNA,16e18 however the largest study to date into
sac expansion rates in patients with HNA was conducted by
Schanzer,9 who analysed 10,228 patients. This study concluded that
endoleaks, aortic neck diameter > 28 mm, aortic neck angle >60,
and common iliac artery diameter >20 mm were all associated
with an increased rate of sac expansion, and suggested that these
patients were at an increased risk of rupture. Our results contradict
the ﬁndings by Schanzer as HNA was not associated with sac
expansion in our study, and was in fact more common in patients
with favourable neck anatomy.
There are several imitations of this study. Although the data for
this study were mostly collected prospectively and merged from
two databases, missing data was supplemented by retrospective
analysis of typed operation notes and electronic medical records.
Themethod ofmeasuring neck diameterwas a singlemeasurement
just below the renal arteries, rather than a 3 point measurement
including at 10 mm and 15 mm below the renal arteries. Never-
theless the completion of data collectionwas excellent and the vastmajority of EVAR patients were followed up, with subsequent
detailed entry of their outcomes into the endovascular stent clinic
database. As there were two dedicated vascular nurse specialists
involved in the management of these endovascular stent clinics,
patients who failed to turn up for surveillance were investigated
further as to whether they had died in the community or else-
where; and the causes of death were ascertained from the elec-
tronic medical records, and the Register Ofﬁce of Leicester City
Council. A further limitation is that aortic anatomical measure-
ments were not recorded at the time of re-intervention, therefore
analysis of change in aortic neck or iliac diameter prior to re-
intervention was not known.
Another limitation of this study relates to the length of follow-up.
Although this study reports the longest follow up for any cohort of
patients with HNA, the total number reaching mid-term (5 year)
surveillance was small, and true long-term (10 year) data was not
possible. Barnes30 identiﬁed aortic neck angle >45, aortic neck
diameter greater than 22 mm and neck length less than 20 mm as
associated with poorer 5 year outcomes following EVAR, however
the criteria used in Barnes arewell within themanufacturer’s IFU for
all endografts, and not representative of hostile neck anatomy. Our
mid-termall causemortality results showednodifference inpatients
withHNA, however truemid-termand long-termresults forpatients
with HNA remain a necessity to guide future stent-graft use.Conclusion
Patients with hostile neck anatomy in terms of increased neck
diameter, severe angulation, neck length, neck thrombus, and neck
ﬂare can be successfully treated with EVAR, with no increase in
mortality rates, and signiﬁcantly improved mortality when
compared to open AAA surgery. However there is an increased risk
of type I endoleaks and reintervention rates in this group of
patients. It is therefore vital that an effective postoperative
surveillance programme is in place to detect and treat serious graft
related complications in such patients. Further work is necessary to
deﬁne whether there is a role for increasing the intensity of
surveillance in these at risk group of patients. With the improve-
ments in endograft design, leading to liberalisation of the recom-
mended instructions for use, as well as the improvements in
intraoperative adjuncts, it is likely that outcomes following EVAR
shall improve in patients with hostile neck anatomy.Funding
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